COVID-19-associated myocarditis: Difference between revisions
Jump to navigation
Jump to search
(→Gender) |
|||
| Line 27: | Line 27: | ||
*The exact mechanisms of [[COVID-19]] induced [[myocarditis]] are not yet well known, although several have been proposed based on the limited data outside of case reports. | *The exact mechanisms of [[COVID-19]] induced [[myocarditis]] are not yet well known, although several have been proposed based on the limited data outside of case reports. | ||
===Proposed pathophysiologies of COVID-19 associated myocarditis=== | ===Proposed pathophysiologies of COVID-19 associated myocarditis=== | ||
*Direct [[myocardial injury]] by binding of [[SARS-COV-2 virus]] through [[ACE2]] [[receptors]] | |||
*[[Systemic inflammatory response syndrome]][[SIRS]] | |||
*[[Hypoxia]] leading to [[supply-demand mismatch]] | |||
*Diffuse vasculitis and [[endothelial inflammation]] in the [[heart]] | |||
*'''Direct invasion of the virus into cardiomyocytes''': | *'''Direct invasion of the virus into cardiomyocytes''': | ||
**[[COVID-19]] infection is caused by [[receptor-mediated endocytosis]] via binding of the [[viral]] [[surface spike]] [[protein]] (primed by [[TMPRSS2]] - [[TMPRSS2|Transmembrane Protease Serine 2]]) to the human [[angiotensin-converting enzyme 2]] ([[angiotensin-converting enzyme 2|ACE2]]) [[receptor]].<ref name="HoffmannKleine-Weber2020">{{cite journal|last1=Hoffmann|first1=Markus|last2=Kleine-Weber|first2=Hannah|last3=Schroeder|first3=Simon|last4=Krüger|first4=Nadine|last5=Herrler|first5=Tanja|last6=Erichsen|first6=Sandra|last7=Schiergens|first7=Tobias S.|last8=Herrler|first8=Georg|last9=Wu|first9=Nai-Huei|last10=Nitsche|first10=Andreas|last11=Müller|first11=Marcel A.|last12=Drosten|first12=Christian|last13=Pöhlmann|first13=Stefan|title=SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor|journal=Cell|volume=181|issue=2|year=2020|pages=271–280.e8|issn=00928674|doi=10.1016/j.cell.2020.02.052}}</ref><ref name="WanShang2020">{{cite journal|last1=Wan|first1=Yushun|last2=Shang|first2=Jian|last3=Graham|first3=Rachel|last4=Baric|first4=Ralph S.|last5=Li|first5=Fang|last6=Gallagher|first6=Tom|title=Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus|journal=Journal of Virology|volume=94|issue=7|year=2020|issn=0022-538X|doi=10.1128/JVI.00127-20}}</ref> | **[[COVID-19]] infection is caused by [[receptor-mediated endocytosis]] via binding of the [[viral]] [[surface spike]] [[protein]] (primed by [[TMPRSS2]] - [[TMPRSS2|Transmembrane Protease Serine 2]]) to the human [[angiotensin-converting enzyme 2]] ([[angiotensin-converting enzyme 2|ACE2]]) [[receptor]].<ref name="HoffmannKleine-Weber2020">{{cite journal|last1=Hoffmann|first1=Markus|last2=Kleine-Weber|first2=Hannah|last3=Schroeder|first3=Simon|last4=Krüger|first4=Nadine|last5=Herrler|first5=Tanja|last6=Erichsen|first6=Sandra|last7=Schiergens|first7=Tobias S.|last8=Herrler|first8=Georg|last9=Wu|first9=Nai-Huei|last10=Nitsche|first10=Andreas|last11=Müller|first11=Marcel A.|last12=Drosten|first12=Christian|last13=Pöhlmann|first13=Stefan|title=SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor|journal=Cell|volume=181|issue=2|year=2020|pages=271–280.e8|issn=00928674|doi=10.1016/j.cell.2020.02.052}}</ref><ref name="WanShang2020">{{cite journal|last1=Wan|first1=Yushun|last2=Shang|first2=Jian|last3=Graham|first3=Rachel|last4=Baric|first4=Ralph S.|last5=Li|first5=Fang|last6=Gallagher|first6=Tom|title=Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus|journal=Journal of Virology|volume=94|issue=7|year=2020|issn=0022-538X|doi=10.1128/JVI.00127-20}}</ref> | ||
Revision as of 05:50, 17 October 2021
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
For COVID-19 patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mounika Reddy Vadiyala, M.B.B.S.[2]
Synonyms and keywords: Novel coronavirus, COVID-19, Wuhan coronavirus, coronavirus disease-19, coronavirus disease 2019, SARS-CoV-2, COVID-19, COVID-19, 2019-nCoV, 2019 novel coronavirus, cardiovascular finding in COVID-19, myocardial injury in COVID-19, myocarditis, myocarditis in COVID-19, COVID-19-associated myocarditis, SARS-CoV2-associated myocarditis, myocardial injury in COVID-19, COVID-19 myocarditis
Overview
COVID-19 caused by the novel coronavirus, also known as SARS-CoV-2 mainly affects the lungs, causing severe acute respiratory syndrome (SARS). It invades through the angiotensin-converting enzyme 2 (ACE2) receptors present abundantly not only in the lungs but also in the heart, kidneys, intestine, brain, skin thus causing multiorgan dysfunction. Studies have demonstrated that COVID-19 interacts with the cardiovascular system, thereby causing myocardial injury and dysfunction as well as increasing morbidity among patients with underlying cardiovascular conditions. Myocardial injury is relatively common in patients with COVID-19, accounting for 7%-23% of cases, and is associated with a higher rate of morbidity and mortality. Myocarditis is a potentially lethal complication of COVID-19. Although many anecdotal reports of myocarditis have been noted, there are only a handful of case reports in the literature about myocarditis related to COVID-19. The exact pathophysiology of COVID-19-associated myocarditis is still elusive; but the proposed mechanisms involve direct invasion through ACE2 receptors and cytokine storm. If untreated, it may lead to life-threatening complications such as cardiogenic shock, heart failure and even death. Supportive care remains the mainstay of treatment.
Historical Perspective
- The novel coronavirus, SARS-CoV-2, is identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in late December 2019. It was named SARS-CoV-2 for its similarity severe acute respiratory syndrome related coronaviruses such as SARS-CoV, which caused acute respiratory distress syndrome (ARDS) in 2002–2003.[1][2]
- On January 30, 2020,the World Health Organization(WHO) declared the outbreak as a Public Health Emergency of International Concern.
- On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic.
- On March 27, 2020, Inciardi et al., from Italy, reported the first case of acute myocardial inflammation in a patient with COVID-19.[3]
Classification
- There is no established system for the classification of the myocarditis seen in COVID-19.
- For general classification of myocarditis, click here.
Pathophysiology
- Myocarditis is an inflammatory disease of the heart characterized by inflammatory infiltrates and myocardial injury without an ischemic cause.[4]
- The major cause of myocarditis in the United States and other developed countries is viral.[5] [6]
- The exact mechanisms of COVID-19 induced myocarditis are not yet well known, although several have been proposed based on the limited data outside of case reports.
Proposed pathophysiologies of COVID-19 associated myocarditis
- Direct myocardial injury by binding of SARS-COV-2 virus through ACE2 receptors
- Systemic inflammatory response syndromeSIRS
- Hypoxia leading to supply-demand mismatch
- Diffuse vasculitis and endothelial inflammation in the heart
- Direct invasion of the virus into cardiomyocytes:
- COVID-19 infection is caused by receptor-mediated endocytosis via binding of the viral surface spike protein (primed by TMPRSS2 - Transmembrane Protease Serine 2) to the human angiotensin-converting enzyme 2 (ACE2) receptor.[7][8]
- ACE2 is expressed in the lung, principally type II alveolar cells which appears to be the principal portal of entry.[9]
- ACE2 is highly expressed in the heart as well.[10]
- However, there are limited reports showing pathological evidence that COVID-19 directly invades the heart.[11]
- Hyperinflammation and Cytokine storm
- Naive T lymphocytes can be primed for viral antigens via antigen-presenting cells.[12]
- The primed CD8+ T lymphocytes migrate to the cardiomyocytes and through cell-mediated cytotoxicity, cause myocardial inflammation and cardio-tropism by heart-produced Hepatocyte Growth Factor (HGF) which interacts with c-Met, an HGF receptor on naïve T lymphocytes.[12]
- In the cytokine storm syndrome, proinflammatory cytokines such as Interleukin-6 (IL-6) are released into the circulation, which further augments T-lymphocyte activation and causes the release of more cytokines.[13]
- Cytokine storms result in increased vascular wall permeabilityand myocardial edema.[14][15]
- A positive feedback loop of immune activation and myocardial damage is established.[16][4]
- Thus cytokine storm activated by T helper cells (Th1 and Th2) and a systemic hyperinflammatory response is triggered.[17][18]
Pathological changes in the myocardium
- They could be due to viral replication in the myocardium or immune responses caused by the infection or due to systemic responses to respiratory failure.
- Interstitial mononuclear inflammatory infiltration has been observed in the heart tissue in COVID-19 autopsy studies.[19]
- In one of the autopsy studies of myocarditis in COVID-19, the viral particles were observed in interstitial cytopathic macrophages. Cardiac myocytes showed non‐specific features consisting of focal myofibrillar lysis, and lipid droplets but no viral particles in myocytes and endothelia; small intramural vessels were free from vasculitis and thrombosis.[11]
- Diffuse lymphocytic inflammatory infiltration was the most common histopathologic finding among 42 cases of myocarditis associated COVID-19 in literature.[21]
Causes
Myocarditis in COVID-19 is caused by:
- Direct invasion of endothelial cells by SARS-CoV-2
- Pro-inflammatory cytokine storm
Differentiating COVID-19 associated myocarditis from other Diseases
For further information about the differential diagnosis, click here.
For further information about the differential diagnosis of COVID-19, click here.
Epidemiology and Demographics
- The incidence of myocardial injury among patients with COVID-19 was approximately 244,000 per 100,000 hospitalized COVID-19 patients.[22]
- In a cohort study the incidence of acute cardiac injury caused by COVID-19 was 19.7% of patients out of 416 hospitalized covid-19 patients whether the portion of them is believed to be myocarditis.[23]
- The prevalence of myocarditis among COVID-19 patients has not yet been reported. Though many anecdotal reports of myocarditis have been noted, there are only a few case reports of myocarditis related to COVID-19.[23][15][3][14][24][25][11][26][27][28]
Age
- Among reported cases in the literature, myocarditis associated COVID-19 was more commonly observed among young patients with a median age of 43.4 years.[21]
- Myocarditis after vaccination of covid-19 was commonly observed in young male.[29]
Gender
- Males are more commonly affected with myocarditis associated COVID-19 than females based on the reported cases in literature.
Race
- There is no data on racial predilection to myocarditis in COVID-19.
Risk Factors
- There are no established risk factors for myocarditis, however the prevalence of COVID-19-associated myocarditis has been more in elderly patients [age>50] and patients with pre-existing cardiovascular diseases.[30][23]
Screening
- There is insufficient evidence to recommend routine screening for myocarditis in COVID-19 patients.
Natural History, Complications and Prognosis
Natural history
- If left untreated, myocarditis of patients with COVID-19 may progress to to cardiogenic shock, heart failure, and eventually can lead to death.[26]
- Myocarditis has also been reported as the cause of death in some COVID-19 patients.[31]
Complications
Common complications of myocarditis include:
- Dilated cardiomyopathy
- Acute-onset heart failure
- Pericarditis
- Ventricular dysfunction
- Arrhythmias
- Sudden cardiac death
Prognosis
- Prognosis is generally poor.
- A retrospective analysis of the cause of death in Chinese patients infected with COVID-19 revealed that 40% of patients died at least in part due to myocardial injury and circulatory collapse.[31]
- In another study, patients hospitalized for COVID-19 infection developed cardiac injury in approximately 20% of cases; thus leading to greater than 50% mortality.[23]
Diagnosis
Diagnostic Criteria
- The diagnosis of myocarditis cannot be made with a single test or examination. When indicated, the diagnosis requires a combination of:
Signs and Symptoms
Clinical presentations have varied in the reported COVID-19 cases with myocarditis in the literature with potential overlap in symptomatology in patients with primary COVID-19 infection and COVID-19 patients with clinically suspected myocarditis. Clinical presentation of COVID-19 related myocarditis varies among cases from mild to severe to fulminant.
- Mild - fatigue and dyspnea, chest pain or chest tightness on exertion.[3][14][15][24]
- Severe - Many patients deteriorate and show symptoms of tachycardia and acute-onset heart failure with cardiogenic shock.[15][3][14]
- Patients may also present with signs of right-sided heart failure, including the following:[6]
- Fulminant - Fulminant myocarditis is defined as ventricular dysfunction and heart failure within 2–3 weeks of infection.[4][32][25][33]
- The early signs of fulminant myocarditis resemble those of sepsis: Fever, low pulse pressure, cold extremities, and sinus tachycardia.[6][15]
- According to a study, ventricular arrhythmia has also been known to occur in patients with myocarditis.[34]
Physical Examination
- Physical examination of patients with severe myocarditis may find:
- Physical examination of patients with fulminant myocarditis may find:
Laboratory Findings
Inflammatory biomarkers
- Elevated levels of inflammatory markers including erythrocyte sedimentation rate, C reactive protein, and procalcitonin are usually seen in myocarditis but they are not specific and do not confirm the diagnosis.
- Increases levels of Interleukin-6 (IL-6), d-dimer, serum ferritin, prothrombin time were seen in COVID-19 patients.[23][13]
Cardiac biomarkers
- Levels of cardiac enzymes such as cardiac troponins (cardiac troponin I(cTnI) and cardiac troponin T (cTnT)) and natriuretic peptides (N-terminal pro-B-type natriuretic peptide (NT-proBNP), and Brain natriuretic peptide (BNP)) usually are elevated in myocarditis due to acute myocardial injury and possible ventricular dilation.
- Elevations of both troponin and NT-proBNP levels were observed in the COVID-19–related myocarditis cases.[15][3][14][24][32][35]
- Elevated NT-proBNP level has been associated with worse clinical outcomes in severe COVID-19 patients.[36][37]
- Cardiac troponins and brain natriuretic peptides are sensitive but not specific in the diagnosis of myocarditis. It requires other supplementary findings and investigations.[38][39][40]
- Although a negative troponin result cannot exclude myocarditis, negative serial high-sensitivity cardiac troponin (hs-cTn) still is helpful in the acute phase and makes the diagnosis of acute myocarditis significantly less likely.[41]
Electrocardiogram
- Normal ECG
- Sinus tachycardia
- ST-segment elevation
- T wave inversion
- ST depression
- Atrial fibrillation
- PVCs
- Supraventricular tachycardia
Echocardiography
- Common findings of echocardiography among reported cases of myocarditis associated covid-19 are left ventricular systolic dysfunction and increased heartsize.[21]
- Findings of echocardiogram in myocarditis are increased wall thickness, ventricular dilation, diffuse hypokinesia/dyskinesia, and pericardial effusion in the background of ventricular systolic dysfunction.[49][50][5]
- These findings were noted in COVID-19 related myocarditis cases.[14][3][15]
Cardiac Magnetic Resonance
- Cardiac Magnetic Resonance (CMR) imaging is a vital test in the diagnosis of myocarditis, especially if an endomyocardial biopsy (EMB) is not pursued or cannot be obtained, before the COVID-19 pandemic.[51]
- Cardiac Magnetic resonance (CMR) has major imaging advantages with highest diagnostic accuracy over echocardiography.[52]
- CMR is not indicated in unstable patients who present with severe heart failure, circulatory shock, ventricular arrhythmia, or high-grade AV block and an EMB should be obtained.[53]
- CMR using the revised Lake Louise consensus criteria to interpret the results has a specificity of up to 91% and a sensitivity of 67% for diagnosing myocarditis.[53]
- If available and there are no contraindications, CMR can safely be used as a first-line diagnostic tool in myocarditis associated with COVID-19.[54]
- In all of the COVID-19–related myocarditis cases for which CMR results were reported, myocardial edema and/or scarring were observed.[3][14][24][26][35][27]
Cardiac Computed Tomography
- Cardiac computed tomography scan (CT scan) with contrast enhancement and ECG gating is an effective alternative to CMR in terms of rapid testing and minimal requirement of breath-holding, especially when the patient has to undergo a high-resolution CT scan (HRCT) of the chest for assessment of acute respiratory distress syndrome.
- Myocardial hypertrophy due to edema was observed in COVID-19 related myocarditis.[14]
Endomyocardial biopsy
- Endomyocardial biopsy (EMB) has been recommended as the definitive diagnostic tool for myocarditis by the American Heart Association (AHA) and European Society of Cardiology (ESC).[55]
- In non–COVID-19 cases, endomyocardial biopsy has traditionally been recommended in fulminant presentations to exclude the rare presentation of eosinophilic, hypersensitive,and giant cell myocarditis.[56]
- However, in COVID-19, it may not be feasible because of the instability of the patient, requirement of expertise, false-negative rate and risk of contagiousness, especially if the biopsy results would not change clinical management.[5][6][52]
- EMB samples if obtained should be tested for inflammatory infiltrates and for the presence of viral genomes by DNA/RNA extraction.[5]
- In a COVID-19 case reported, EMB showed diffuse T-lymphocytic inflammatory infiltrates with huge interstitial edema and no replacement fibrosis, suggesting an acute inflammatory process. SARS-CoV-2 genome was absent within the myocardium in molecular analysis.[24]
Treatment
Medical Therapy
- There is no definitive treatment for COVID-19-associated myocarditis; the mainstay of therapy is supportive care because no specific effective anti-viral therapies have been identified.
- As per AHA recommendations, in the patients of fulminant myocarditis, initial management includes the protocol of cardiogenic shock which is the administration of inotropes and/vasopressors and mechanical ventilation; and use of extracorporeal membrane oxygenation(ECMO), ventricular assistive devices (VAD) in severe cases.[15][57][32][3][25]
- This protocol has been the mainstay of treatment in COVID-19-associated myocarditis cases as well and proved beneficial in mitigating ventricular systolic dysfunction.
- Though the European Society of Cardiology (ESC) did not approve the use of intravenous immunoglobulins (IVIG) and corticosteroids in active-infection myocarditis, COVID-19-associated myocarditis cases have been reported in which use of immunoglobulins and corticosteroids such as methylprednisolone and hydrocortisone have been beneficial.[25][15][3][35][26]
- Tocilizumab, an anti–IL-6 receptor monoclonal antibody, is being tested in a randomized controlled trial of COVID-19 patients with raised IL-6 levels.
- Tocilizumab, might be beneficial in the setting of cytokine storm syndrome and help reduce myocardial inflammation.[41]
- Although the cases of COVID-19 patients with myocarditis were treated with steroids and immunoglobulins, it is uncertain the incremental benefit these therapies might have provided over supportive care.
- Further evidence is needed to determine whether any combination of immunosuppression improves outcomes among patients with myocarditis in COVID-19.
Surgery
- Surgical intervention is not recommended for the management of COVID-19-associated myocarditis.
Primary Prevention
- There are no established measures for the primary prevention of COVID-19-associated myocarditis.
- For primary preventive measures of [COVID-19], click here.
Secondary Prevention
- There are no established measures for the secondary prevention of COVID-19-associated myocarditis.
- For secondary preventive measures of [COVID-19], click here.
References
- ↑ Lu, Jian; Cui, Jie; Qian, Zhaohui; Wang, Yirong; Zhang, Hong; Duan, Yuange; Wu, Xinkai; Yao, Xinmin; Song, Yuhe; Li, Xiang; Wu, Changcheng; Tang, Xiaolu (2020). "On the origin and continuing evolution of SARS-CoV-2". National Science Review. doi:10.1093/nsr/nwaa036. ISSN 2095-5138.
- ↑ Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". The Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 Inciardi, Riccardo M.; Lupi, Laura; Zaccone, Gregorio; Italia, Leonardo; Raffo, Michela; Tomasoni, Daniela; Cani, Dario S.; Cerini, Manuel; Farina, Davide; Gavazzi, Emanuele; Maroldi, Roberto; Adamo, Marianna; Ammirati, Enrico; Sinagra, Gianfranco; Lombardi, Carlo M.; Metra, Marco (2020). "Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)". JAMA Cardiology. doi:10.1001/jamacardio.2020.1096. ISSN 2380-6583.
- ↑ 4.0 4.1 4.2 Esfandiarei, Mitra; McManus, Bruce M. (2008). "Molecular Biology and Pathogenesis of Viral Myocarditis". Annual Review of Pathology: Mechanisms of Disease. 3 (1): 127–155. doi:10.1146/annurev.pathmechdis.3.121806.151534. ISSN 1553-4006.
- ↑ 5.0 5.1 5.2 5.3 Caforio, A. L. P.; Pankuweit, S.; Arbustini, E.; Basso, C.; Gimeno-Blanes, J.; Felix, S. B.; Fu, M.; Helio, T.; Heymans, S.; Jahns, R.; Klingel, K.; Linhart, A.; Maisch, B.; McKenna, W.; Mogensen, J.; Pinto, Y. M.; Ristic, A.; Schultheiss, H.-P.; Seggewiss, H.; Tavazzi, L.; Thiene, G.; Yilmaz, A.; Charron, P.; Elliott, P. M. (2013). "Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases". European Heart Journal. 34 (33): 2636–2648. doi:10.1093/eurheartj/eht210. ISSN 0195-668X.
- ↑ 6.0 6.1 6.2 6.3 Kociol, Robb D.; Cooper, Leslie T.; Fang, James C.; Moslehi, Javid J.; Pang, Peter S.; Sabe, Marwa A.; Shah, Ravi V.; Sims, Daniel B.; Thiene, Gaetano; Vardeny, Orly (2020). "Recognition and Initial Management of Fulminant Myocarditis". Circulation. 141 (6). doi:10.1161/CIR.0000000000000745. ISSN 0009-7322.
- ↑ Hoffmann, Markus; Kleine-Weber, Hannah; Schroeder, Simon; Krüger, Nadine; Herrler, Tanja; Erichsen, Sandra; Schiergens, Tobias S.; Herrler, Georg; Wu, Nai-Huei; Nitsche, Andreas; Müller, Marcel A.; Drosten, Christian; Pöhlmann, Stefan (2020). "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor". Cell. 181 (2): 271–280.e8. doi:10.1016/j.cell.2020.02.052. ISSN 0092-8674.
- ↑ Wan, Yushun; Shang, Jian; Graham, Rachel; Baric, Ralph S.; Li, Fang; Gallagher, Tom (2020). "Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus". Journal of Virology. 94 (7). doi:10.1128/JVI.00127-20. ISSN 0022-538X.
- ↑ Zhao, Yu; Zhao, Zixian; Wang, Yujia; Zhou, Yueqing; Ma, Yu; Zuo, Wei (2020). doi:10.1101/2020.01.26.919985. Missing or empty
|title=(help) - ↑ Tikellis, Chris; Thomas, M. C. (2012). "Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease". International Journal of Peptides. 2012: 1–8. doi:10.1155/2012/256294. ISSN 1687-9767.
- ↑ 11.0 11.1 11.2 Tavazzi, Guido; Pellegrini, Carlo; Maurelli, Marco; Belliato, Mirko; Sciutti, Fabio; Bottazzi, Andrea; Sepe, Paola Alessandra; Resasco, Tullia; Camporotondo, Rita; Bruno, Raffaele; Baldanti, Fausto; Paolucci, Stefania; Pelenghi, Stefano; Iotti, Giorgio Antonio; Mojoli, Francesco; Arbustini, Eloisa (2020). "Myocardial localization of coronavirus in COVID‐19 cardiogenic shock". European Journal of Heart Failure. 22 (5): 911–915. doi:10.1002/ejhf.1828. ISSN 1388-9842.
- ↑ 12.0 12.1 Komarowska, Izabela; Coe, David; Wang, Guosu; Haas, Robert; Mauro, Claudio; Kishore, Madhav; Cooper, Dianne; Nadkarni, Suchita; Fu, Hongmei; Steinbruchel, Daniel A.; Pitzalis, Costantino; Anderson, Graham; Bucy, Pat; Lombardi, Giovanna; Breckenridge, Ross; Marelli-Berg, Federica M. (2015). "Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release". Immunity. 42 (6): 1087–1099. doi:10.1016/j.immuni.2015.05.014. ISSN 1074-7613.
- ↑ 13.0 13.1 Zhou, Fei; Yu, Ting; Du, Ronghui; Fan, Guohui; Liu, Ying; Liu, Zhibo; Xiang, Jie; Wang, Yeming; Song, Bin; Gu, Xiaoying; Guan, Lulu; Wei, Yuan; Li, Hui; Wu, Xudong; Xu, Jiuyang; Tu, Shengjin; Zhang, Yi; Chen, Hua; Cao, Bin (2020). "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study". The Lancet. 395 (10229): 1054–1062. doi:10.1016/S0140-6736(20)30566-3. ISSN 0140-6736.
- ↑ 14.0 14.1 14.2 14.3 14.4 14.5 14.6 14.7 Han, Seongwook; Kim, Hyun Ah; Kim, Jin Young; Kim, In-Cheol (2020). "COVID-19-related myocarditis in a 21-year-old female patient". European Heart Journal. 41 (19): 1859–1859. doi:10.1093/eurheartj/ehaa288. ISSN 0195-668X.
- ↑ 15.0 15.1 15.2 15.3 15.4 15.5 15.6 15.7 15.8 Zeng, Jia-Hui; Liu, Ying-Xia; Yuan, Jing; Wang, Fu-Xiang; Wu, Wei-Bo; Li, Jin-Xiu; Wang, Li-Fei; Gao, Hong; Wang, Yao; Dong, Chang-Feng; Li, Yi-Jun; Xie, Xiao-Juan; Feng, Cheng; Liu, Lei (2020). "First case of COVID-19 complicated with fulminant myocarditis: a case report and insights". Infection. doi:10.1007/s15010-020-01424-5. ISSN 0300-8126.
- ↑ Iakimov VP (1977). "[F. Engels' theory of the origin of man and modern anthropologic findings]". Arkh Anat Gistol Embriol. 72 (6): 5–11. PMID 409380.
- ↑ Mehta, Puja; McAuley, Daniel F; Brown, Michael; Sanchez, Emilie; Tattersall, Rachel S; Manson, Jessica J (2020). "COVID-19: consider cytokine storm syndromes and immunosuppression". The Lancet. 395 (10229): 1033–1034. doi:10.1016/S0140-6736(20)30628-0. ISSN 0140-6736.
- ↑ Chen, Guang; Wu, Di; Guo, Wei; Cao, Yong; Huang, Da; Wang, Hongwu; Wang, Tao; Zhang, Xiaoyun; Chen, Huilong; Yu, Haijing; Zhang, Xiaoping; Zhang, Minxia; Wu, Shiji; Song, Jianxin; Chen, Tao; Han, Meifang; Li, Shusheng; Luo, Xiaoping; Zhao, Jianping; Ning, Qin (2020). "Clinical and immunological features of severe and moderate coronavirus disease 2019". Journal of Clinical Investigation. 130 (5): 2620–2629. doi:10.1172/JCI137244. ISSN 0021-9738.
- ↑ Xu, Zhe; Shi, Lei; Wang, Yijin; Zhang, Jiyuan; Huang, Lei; Zhang, Chao; Liu, Shuhong; Zhao, Peng; Liu, Hongxia; Zhu, Li; Tai, Yanhong; Bai, Changqing; Gao, Tingting; Song, Jinwen; Xia, Peng; Dong, Jinghui; Zhao, Jingmin; Wang, Fu-Sheng (2020). "Pathological findings of COVID-19 associated with acute respiratory distress syndrome". The Lancet Respiratory Medicine. 8 (4): 420–422. doi:10.1016/S2213-2600(20)30076-X. ISSN 2213-2600.
- ↑ "Myocardial localization of coronavirus in COVID‐19 cardiogenic shock".
- ↑ 21.0 21.1 21.2 Rathore SS, Rojas GA, Sondhi M, Pothuru S, Pydi R, Kancherla N, Singh R, Ahmed NK, Shah J, Tousif S, Baloch UT, Wen Q (July 2021). "Myocarditis associated with Covid-19 disease: A systematic review of published case reports and case series". Int J Clin Pract: e14470. doi:10.1111/ijcp.14470. PMID 34235815 Check
|pmid=value (help). - ↑ Zou F, Qian Z, Wang Y, Zhao Y, Bai J (September 2020). "Cardiac Injury and COVID-19: A Systematic Review and Meta-analysis". CJC Open. 2 (5): 386–394. doi:10.1016/j.cjco.2020.06.010. PMC 7308771 Check
|pmc=value (help). PMID 32838255 Check|pmid=value (help). - ↑ 23.0 23.1 23.2 23.3 23.4 Shi, Shaobo; Qin, Mu; Shen, Bo; Cai, Yuli; Liu, Tao; Yang, Fan; Gong, Wei; Liu, Xu; Liang, Jinjun; Zhao, Qinyan; Huang, He; Yang, Bo; Huang, Congxin (2020). "Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China". JAMA Cardiology. doi:10.1001/jamacardio.2020.0950. ISSN 2380-6583.
- ↑ 24.0 24.1 24.2 24.3 24.4 Esposito, Antonio; Godino, Cosmo; Basso, Cristina; Cappelletti, Alberto Maria; Tresoldi, Moreno; De Cobelli, Francesco; Vignale, Davide; Villatore, Andrea; Palmisano, Anna; Gramegna, Mario; Peretto, Giovanni; Sala, Simone (2020). "Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection". European Heart Journal. 41 (19): 1861–1862. doi:10.1093/eurheartj/ehaa286. ISSN 0195-668X.
- ↑ 25.0 25.1 25.2 25.3 Fang, Yuan; Wei, Xin; Ma, Fenglian; Hu, Hongde (2020). "Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin". European Heart Journal. doi:10.1093/eurheartj/ehaa190. ISSN 0195-668X.
- ↑ 26.0 26.1 26.2 26.3 Coyle, Justin; Igbinomwanhia, Efehi; Sanchez-Nadales, Alejandro; Danciu, Sorin; Chu, Chae; Shah, Nishit (2020). "A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001". JACC: Case Reports. doi:10.1016/j.jaccas.2020.04.025. ISSN 2666-0849.
- ↑ 27.0 27.1 Luetkens, Julian Alexander; Isaak, Alexander; Zimmer, Sebastian; Nattermann, Jacob; Sprinkart, Alois Martin; Boesecke, Christoph; Rieke, Gereon Jonas; Zachoval, Christian; Heine, Annkristin; Velten, Markus; Duerr, Georg Daniel (2020). "Diffuse Myocardial Inflammation in COVID-19 Associated Myocarditis Detected by Multiparametric Cardiac Magnetic Resonance Imaging". Circulation: Cardiovascular Imaging. 13 (5). doi:10.1161/CIRCIMAGING.120.010897. ISSN 1941-9651.
- ↑ Beşler, Muhammed Said; Arslan, Halil (2020). "Acute myocarditis associated with COVID-19 infection". The American Journal of Emergency Medicine. doi:10.1016/j.ajem.2020.05.100. ISSN 0735-6757.
- ↑ Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A (September 2021). "Myocarditis and Pericarditis After Vaccination for COVID-19". JAMA. 326 (12): 1210–1212. doi:10.1001/jama.2021.13443. PMID 34347001 Check
|pmid=value (help). - ↑ Guo, Tao; Fan, Yongzhen; Chen, Ming; Wu, Xiaoyan; Zhang, Lin; He, Tao; Wang, Hairong; Wan, Jing; Wang, Xinghuan; Lu, Zhibing (2020). "Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)". JAMA Cardiology. doi:10.1001/jamacardio.2020.1017. ISSN 2380-6583.
- ↑ 31.0 31.1 Ruan, Qiurong; Yang, Kun; Wang, Wenxia; Jiang, Lingyu; Song, Jianxin (2020). "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China". Intensive Care Medicine. 46 (5): 846–848. doi:10.1007/s00134-020-05991-x. ISSN 0342-4642.
- ↑ 32.0 32.1 32.2 Irabien-Ortiz, Ángela; Carreras-Mora, José; Sionis, Alessandro; Pàmies, Julia; Montiel, José; Tauron, Manel (2020). "Fulminant myocarditis due to COVID-19". Revista Española de Cardiología (English Edition). 73 (6): 503–504. doi:10.1016/j.rec.2020.04.005. ISSN 1885-5857.
- ↑ Wang, Daowen; Li, Sheng; Jiang, Jiangang; Yan, Jiangtao; Zhao, Chunxia; Wang, Yan; Ma, Yexin; Zeng, Hesong; Guo, Xiaomei; Wang, Hong; Tang, Jiarong; Zuo, Houjuan; Lin, Li; Cui, Guanglin (2018). "Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis". Science China Life Sciences. 62 (2): 187–202. doi:10.1007/s11427-018-9385-3. ISSN 1674-7305.
- ↑ Peretto, Giovanni; Sala, Simone; Rizzo, Stefania; Palmisano, Anna; Esposito, Antonio; De Cobelli, Francesco; Campochiaro, Corrado; De Luca, Giacomo; Foppoli, Luca; Dagna, Lorenzo; Thiene, Gaetano; Basso, Cristina; Della Bella, Paolo (2020). "Ventricular Arrhythmias in Myocarditis". Journal of the American College of Cardiology. 75 (9): 1046–1057. doi:10.1016/j.jacc.2020.01.036. ISSN 0735-1097.
- ↑ 35.0 35.1 35.2 Doyen, Denis; Moceri, Pamela; Ducreux, Dorothée; Dellamonica, Jean (2020). "Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes". The Lancet. 395 (10235): 1516. doi:10.1016/S0140-6736(20)30912-0. ISSN 0140-6736.
- ↑ Gao, Lei; Jiang, Dan; Wen, Xue-song; Cheng, Xiao-cheng; Sun, Min; He, Bin; You, Lin-na; Lei, Peng; Tan, Xiao-wei; Qin, Shu; Cai, Guo-qiang; Zhang, Dong-ying (2020). "Prognostic value of NT-proBNP in patients with severe COVID-19". Respiratory Research. 21 (1). doi:10.1186/s12931-020-01352-w. ISSN 1465-993X.
- ↑ Han, Huan; Xie, Linlin; Liu, Rui; Yang, Jie; Liu, Fang; Wu, Kailang; Chen, Lang; Hou, Wei; Feng, Yong; Zhu, Chengliang (2020). "Analysis of heart injury laboratory parameters in 273 COVID‐19 patients in one hospital in Wuhan, China". Journal of Medical Virology. 92 (7): 819–823. doi:10.1002/jmv.25809. ISSN 0146-6615.
- ↑ Lauer, Bernward; Niederau, Christoph; Kühl, Uwe; Schannwell, Mira; Pauschinger, Matthias; Strauer, Bodo-Eckhard; Schultheiss, Heinz-Peter (1997). "Cardiac Troponin T in Patients With Clinically Suspected Myocarditis". Journal of the American College of Cardiology. 30 (5): 1354–1359. doi:10.1016/S0735-1097(97)00317-3. ISSN 0735-1097.
- ↑ Heymans, S. (2007). "Myocarditis and heart failure: need for better diagnostic, predictive, and therapeutic tools". European Heart Journal. 28 (11): 1279–1280. doi:10.1093/eurheartj/ehm111. ISSN 0195-668X.
- ↑ Jensen, Juliana; Ma, Li-Ping; Fu, Michael L. X.; Svaninger, David; Lundberg, Per-Arne; Hammarsten, Ola (2010). "Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio". Clinical Research in Cardiology. 99 (7): 445–452. doi:10.1007/s00392-010-0140-z. ISSN 1861-0684.
- ↑ 41.0 41.1 Siripanthong, Bhurint; Nazarian, Saman; Muser, Daniele; Deo, Rajat; Santangeli, Pasquale; Khanji, Mohammed Y.; Cooper, Leslie T.; Chahal, C. Anwar A. (2020). "Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management". Heart Rhythm. doi:10.1016/j.hrthm.2020.05.001. ISSN 1547-5271.
- ↑ Juusela A, Nazir M, Gimovsky M (May 2020). "Two cases of coronavirus 2019-related cardiomyopathy in pregnancy". Am J Obstet Gynecol MFM. 2 (2): 100113. doi:10.1016/j.ajogmf.2020.100113. PMC 7194868 Check
|pmc=value (help). PMID 32363336 Check|pmid=value (help). - ↑ Kim IC, Kim JY, Kim HA, Han S (May 2020). "COVID-19-related myocarditis in a 21-year-old female patient". Eur Heart J. 41 (19): 1859. doi:10.1093/eurheartj/ehaa288. PMC 7184491 Check
|pmc=value (help). PMID 32282027 Check|pmid=value (help). - ↑ Favre G, Pomar L, Baud D (August 2020). "Coronavirus disease 2019 during pregnancy: do not underestimate the risk of maternal adverse outcomes". Am J Obstet Gynecol MFM. 2 (3): 100160. doi:10.1016/j.ajogmf.2020.100160. PMC 7367790 Check
|pmc=value (help). PMID 32838265 Check|pmid=value (help). - ↑ Sardari A, Tabarsi P, Borhany H, Mohiaddin R, Houshmand G (January 2021). "Myocarditis detected after COVID-19 recovery". Eur Heart J Cardiovasc Imaging. 22 (1): 131–132. doi:10.1093/ehjci/jeaa166. PMC 7574602 Check
|pmc=value (help). PMID 32462177 Check|pmid=value (help). - ↑ Luetkens JA, Isaak A, Zimmer S, Nattermann J, Sprinkart AM, Boesecke C, Rieke GJ, Zachoval C, Heine A, Velten M, Duerr GD (May 2020). "Diffuse Myocardial Inflammation in COVID-19 Associated Myocarditis Detected by Multiparametric Cardiac Magnetic Resonance Imaging". Circ Cardiovasc Imaging. 13 (5): e010897. doi:10.1161/CIRCIMAGING.120.010897. PMID 32397816 Check
|pmid=value (help). - ↑ Yokoo P, Fonseca E, Sasdelli Neto R, Ishikawa WY, Silva M, Yanata E, Chate RC, Nunes Filho A, Bettega M, Fernandes J, Tarasoutchi F, Szarf G (2020). "COVID-19 myocarditis: a case report". Einstein (Sao Paulo). 18: eRC5876. doi:10.31744/einstein_journal/2020RC5876. PMC 7575039 Check
|pmc=value (help). PMID 33111813 Check|pmid=value (help). Vancouver style error: initials (help) - ↑ Khalid Y, Dasu N, Dasu K (August 2020). "A case of novel coronavirus (COVID-19)-induced viral myocarditis mimicking a Takotsubo cardiomyopathy". HeartRhythm Case Rep. 6 (8): 473–476. doi:10.1016/j.hrcr.2020.05.020. PMC 7424304 Check
|pmc=value (help). PMID 32817822 Check|pmid=value (help). - ↑ Pinamonti, Bruno; Alberti, Ezip; Cigalotto, Alessandro; Dreas, Lorella; Salvi, Alessandro; Silvestri, Furio; Camerini, Fulvio (1988). "Echocardiographic findings in myocarditis". The American Journal of Cardiology. 62 (4): 285–291. doi:10.1016/0002-9149(88)90226-3. ISSN 0002-9149.
- ↑ Felker, G.Michael; Boehmer, John P; Hruban, Ralph H; Hutchins, Grover M; Kasper, Edward K; Baughman, Kenneth L; Hare, Joshua M (2000). "Echocardiographic findings in fulminant and acute myocarditis". Journal of the American College of Cardiology. 36 (1): 227–232. doi:10.1016/S0735-1097(00)00690-2. ISSN 0735-1097.
- ↑ Ezekowitz, Justin A.; O'Meara, Eileen; McDonald, Michael A.; Abrams, Howard; Chan, Michael; Ducharme, Anique; Giannetti, Nadia; Grzeslo, Adam; Hamilton, Peter G.; Heckman, George A.; Howlett, Jonathan G.; Koshman, Sheri L.; Lepage, Serge; McKelvie, Robert S.; Moe, Gordon W.; Rajda, Miroslaw; Swiggum, Elizabeth; Virani, Sean A.; Zieroth, Shelley; Al-Hesayen, Abdul; Cohen-Solal, Alain; D'Astous, Michel; De, Sabe; Estrella-Holder, Estrellita; Fremes, Stephen; Green, Lee; Haddad, Haissam; Harkness, Karen; Hernandez, Adrian F.; Kouz, Simon; LeBlanc, Marie-Hélène; Masoudi, Frederick A.; Ross, Heather J.; Roussin, Andre; Sussex, Bruce (2017). "2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure". Canadian Journal of Cardiology. 33 (11): 1342–1433. doi:10.1016/j.cjca.2017.08.022. ISSN 0828-282X.
- ↑ 52.0 52.1 Friedrich, Matthias G.; Strohm, Oliver; Schulz-Menger, Jeanette; Marciniak, Heinz; Luft, Friedrich C.; Dietz, Rainer (1998). "Contrast Media–Enhanced Magnetic Resonance Imaging Visualizes Myocardial Changes in the Course of Viral Myocarditis". Circulation. 97 (18): 1802–1809. doi:10.1161/01.CIR.97.18.1802. ISSN 0009-7322.
- ↑ 53.0 53.1 Friedrich, Matthias G.; Sechtem, Udo; Schulz-Menger, Jeanette; Holmvang, Godtfred; Alakija, Pauline; Cooper, Leslie T.; White, James A.; Abdel-Aty, Hassan; Gutberlet, Matthias; Prasad, Sanjay; Aletras, Anthony; Laissy, Jean-Pierre; Paterson, Ian; Filipchuk, Neil G.; Kumar, Andreas; Pauschinger, Matthias; Liu, Peter (2009). "Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper". Journal of the American College of Cardiology. 53 (17): 1475–1487. doi:10.1016/j.jacc.2009.02.007. ISSN 0735-1097.
- ↑ Han, Yuchi; Chen, Tiffany; Bryant, Jennifer; Bucciarelli-Ducci, Chiara; Dyke, Christopher; Elliott, Michael D.; Ferrari, Victor A.; Friedrich, Matthias G.; Lawton, Chris; Manning, Warren J.; Ordovas, Karen; Plein, Sven; Powell, Andrew J.; Raman, Subha V.; Carr, James (2020). "Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic". Journal of Cardiovascular Magnetic Resonance. 22 (1). doi:10.1186/s12968-020-00628-w. ISSN 1532-429X.
- ↑ Dennert, R.; Crijns, H. J.; Heymans, S. (2008). "Acute viral myocarditis". European Heart Journal. 29 (17): 2073–2082. doi:10.1093/eurheartj/ehn296. ISSN 0195-668X.
- ↑ Cooper, Leslie T.; Baughman, Kenneth L.; Feldman, Arthur M.; Frustaci, Andrea; Jessup, Mariell; Kuhl, Uwe; Levine, Glenn N.; Narula, Jagat; Starling, Randall C.; Towbin, Jeffrey; Virmani, Renu (2007). "The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease". Circulation. 116 (19): 2216–2233. doi:10.1161/CIRCULATIONAHA.107.186093. ISSN 0009-7322.
- ↑ Rao, Sangeetha; Sasser, William; Diaz, Franco; Sharma, Nirmal; Alten, Jeffrey (2014). "Coronavirus Associated Fulminant Myocarditis Successfully Treated With Intravenous Immunoglobulin and Extracorporeal Membrane Oxygenation". Chest. 146 (4): 336A. doi:10.1378/chest.1992018. ISSN 0012-3692.